Inflammatory and cell-mediated immune biomarkers in myalgic encephalomyelitis/chronic fatigue syndrome and depression: Inflammatory markers are higher in myalgic encephalomyelitis/chronic fatigue syndrome than in depression

Psychotherapy and Psychosomatics

Volumn 81, Issue 5, 2012, Pages 286-295

  Maes, Michael ^a   Twisk, Frank N M ^b   Ringel, Karl ^c  

^a Piyavate Hospital   (Thailand)

^b ME de patinten Foundation   (Netherlands)

^c Immunologische Laboratorien   (Germany)

Author keywords

Cell mediated immunity; Chronic fatigue; Comorbidity; Cytokines; Depression; Inflammation; Oxidative and nitrosative stress

Indexed keywords

INTERLEUKIN 1; NEOPTERIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CELLULAR IMMUNITY; CHRONIC FATIGUE SYNDROME; COMPARATIVE STUDY; CONTROLLED STUDY; DEPRESSION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; RADIOIMMUNOASSAY;

ADULT; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CYTOKINES; DEPRESSIVE DISORDER, MAJOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FATIGUE SYNDROME, CHRONIC; FEMALE; HUMANS; IMMUNITY, CELLULAR; INFLAMMATION; MALE; NEOPTERIN; SEVERITY OF ILLNESS INDEX;

EID: 84864103871     PISSN: 00333190     EISSN: 14230348     Source Type: Journal    
DOI: 10.1159/000336803     Document Type: Article

References (54)

1. Maes M: Evidence for an immune response in major depression: a review and hypothesis. Prog Neuropsychopharmacol Biol Psychiatry 1995; 19: 11-38.
2. Maes M: Depression is an inflammatory disease, but cell-mediated immune activation is the key component of depression. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35: 664-675.
3. Howren MB, Lamkin DM, Suls J: Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med 2009; 71: 171-186.
4. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, Lanctot KL: A metaanalysis of cytokines in major depression. Biol Psychiatry 2010; 67: 446-457.
5. Liu Y, Ho RC, Mak A: Interleukin (IL)-6, tumour necrosis factor alpha (TNF) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: a metaanalysis and meta-regression. J Affect Disord 2011, E-pub ahead of print.
6. Maes M, Galecki P, Chang YS, Berk M: A review on the oxidative and nitrosative stress (O & NS) pathways in major depression and their possible contribution to the (neuro) degenerative processes in that illness. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35: 676-692.
7. Leonard B, Maes M: Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathobiology of unipolar depression. Neurosci Biobehav Rev 2012; 36: 764-785.
8. Maes M: 'Functional' or 'psychosomatic' symptoms, e.g. a flu-like malaise, aches and pain and fatigue, are major features of major and in particular of melancholic depression. Neuroendocrinol Lett 2009; 30: 564-573.
9. Kellner R: Psychosomatic syndromes, somatization and somatoform disorders. Psychother Psychosom 1994; 61: 4-24.
10. Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A: The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med 1994; 121: 953-959.
11. Maes M: Inflammatory and oxidative and nitrosative stress pathways underpinning chronic fatigue, somatization and psychosomatic symptoms. Curr Opin Psychiatry 2009; 22: 75-83.
12. Maes M, Twisk FN: Chronic fatigue syndrome: Harvey and Wessely's (bio)psychosocial model versus a bio(psychosocial) model based on inflammatory and oxidative and nitrosative stress pathways. BMC Med 2010; 8: 35.
13. Lorusso L, Mikhaylova SV, Capelli E, Ferrari D, Ngonga GK, Ricevuti G: Immunological aspects of chronic fatigue syndrome. Autoimmun Rev 2009; 8: 287-291.
14. Fletcher MA, Zeng XR, Barnes Z, Levis S, Klimas NG: Plasma cytokines in women with chronic fatigue syndrome. J Transl Med 2009; 7: 96.
15. Maes M, Mihaylova I, Kubera M, Bosmans E: Not in the mind but in the cell: increased production of cyclo-oxygenase-2 and inducible NO synthase in chronic fatigue syndrome. Neuroendocrinol Lett 2007; 28: 463-469.
16. Buchwald D, Wener MH, Pearlman T, Kith P: Markers of inflammation and immune activation in chronic fatigue and chronic fatigue syndrome. J Rheumatol 1997; 24: 372-376.
17. Matsuda J, Gohchi K, Gotoh N: Serum concentrations of 2',5, oligoadenylate synthetase, neopterin, and beta-glucan in patients with chronic fatigue syndrome and in patients with major depression. J Neurol Neurosurg Psychiatry 1994; 57: 1015-1016.
18. Chao CC, Gallagher M, Phair J, Peterson PK: Serum neopterin and interleukin-6 levels in chronic fatigue syndrome. J Infect Dis 1990; 162: 1412-1413.
19. Maes M, Mihaylova I, Leunis JC: Chronic fatigue syndrome is accompanied by an IgMrelated immune response directed against neopitopes formed by oxidative or nitrosative damage to lipids and proteins. Neuroendocrinol Lett 2006; 27: 615-621.
20. Sheng WS, Hu S, Lamkin A, Peterson PK, Chao CC: Susceptibility to immunologically mediated fatigue in C57BL/6 versus Balb/c mice. Clin Immunol Immunopathol 1996; 81: 161-167.
21. Sheng WS, Hu S, Ding JM, Chao CC, Peterson PK: Cytokine expression in the mouse brain in response to immune activation by Corynebacterium parvum. Clin Diagn Lab Immunol 2001; 8: 446-448.
22. Cavadini G, Petrzilka S, Kohler P, Jud C, Tobler I, Birchler T, Fontana A: TNF-alpha suppresses the expression of clock genes by interfering with E-box-mediated transcription. Proc Natl Acad Sci USA 2007; 104: 12843-12848.
23. Jiang Y, Deacon R, Anthony DC, Campbell SJ: Inhibition of peripheral TNF can block the malaise associated with CNS inflammatory diseases. Neurobiol Dis 2008; 32: 125-132.
24. Hermann GE, Rogers RC: TNFalpha: a trigger of autonomic dysfunction. Neuroscientist 2008; 14: 53-67.
25. Maes M: An intriguing and hitherto unexplained co-occurrence: depression and chronic fatigue syndrome are manifestations of shared inflammatory, oxidative and nitrosative (IO&NS) pathways. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35: 784-794.
26. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4, text revision (DSM-IV-TR). Washington, American Psychiatric Association, 2000.
27. Zachrisson O, Regland B, Jahreskog M, Kron M, Gottfries CG: A rating scale for fibromyalgia and chronic fatigue syndrome (the FibroFatigue scale). J Psychosom Res 2002; 52: 501-509.
28. Maes M, Twisk FN, Kubera M, Ringel K: Evidence for inflammation and activation of cell-mediated immunity in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): increased interleukin-1, tumor necrosis factor , PMN-elastase, lysozyme and neopterin. J Affect Disord 2012;136:933-939.
29. Maes M, Mihaylova I, Kubera M, Ringel K: Activation of cell-mediated immunity in depression: association with inflammation, melancholia, clinical staging and the fatigue and somatic symptom cluster of depression. Prog Neuropsychopharmacol Biol Psychiatry 2012; 36: 169-175.
30. March CJ, Mosley B, Larsen A, et al: Cloning, sequence and expression of two distinct human interleukin-1 complementary DNAs. Nature 1985; 315: 641-647.
31. Maes M, Rief W: Diagnostic classifications in depression and somatization should include biomarkers, such as disorders in the tryptophan catabolite (TRYCAT) pathway. Psychiatry Res, in press.
32. Patarca R: Cytokines and chronic fatigue syndrome. Ann NY Acad Sci 2001; 933: 185-200.
33. Torres-Harding S, Sorenson M, Jason LA, Maher K, Fletcher MA: Evidence for T-helper 2 shift and association with illness parameters in chronic fatigue syndrome (CFS). Bull IACFS ME 2008; 16: 19-33.
34. Fletcher MA, Zeng XR, Barnes Z, Levis S, Klimas NG: Plasma cytokines in women with chronic fatigue syndrome. J Transl Med 2009; 7: 96.
35. Brenu EW, van Driel ML, Staines DR, Ashton KJ, Ramos SB, Keane J, Klimas NG, Marshall-Gradisnik SM: Immunological abnormalities as potential biomarkers in chronic fatigue syndrome/myalgic encephalomyelitis. J Transl Med 2011; 9: 81.
36. Broderick G, Fuite J, Kreitz A, Vernon SD, Klimas N, Fletcher MA: A formal analysis of cytokine networks in chronic fatigue syndrome. Brain Behav Immun 2010; 24: 1209-1217.
37. Nakamura T, Schwander SK, Donnelly R, Ortega F, Togo F, Broderick G, Yamamoto Y, Cherniack NS, Rapoport D, Natelson BH: Cytokines across the night in chronic fatigue syndrome with and without fibromyalgia. Clin Vaccine Immunol 2010; 17: 582-587.
38. Bellmann-Weiler R, Schroecksnadel K, Holzer C, Larcher C, Fuchs D, Weiss G: IFNgamma mediated pathways in patients with fatigue and chronic active Epstein-Barr virus infection. J Affect Disord 2008; 108: 171-176.
39. Krzyszton CP, Sparkman NL, Grant RW, Buchanan JB, Broussard SR, Woods J, Johnson RW: Exacerbated fatigue and motor deficits in interleukin-10-deficient mice after peripheral immune stimulation. Am J Physiol Regul Integr Comp Physiol 2008; 295:R1109-R1114.
40. Carmichael MD, Davis JM, Murphy EA, Carson JA, Van Rooijen N, Mayer E, Ghaffar A: Role of brain macrophages on IL-1beta and fatigue following eccentric exercise-induced muscle damage. Brain Behav Immun 2010; 24: 564-568.
41. Nakamura M, Ferreira SH: A peripheral sympathetic component in inflammatory hyperalgesia. Eur J Pharmacol 1987; 135: 145-153.
42. Maes M, Van Gastel A, Delmeire L, Kenis G, Bosmans E, Song C: Platelet alpha2 adrenoceptor density in humans: relationships to stress-induced anxiety, psychasthenic constitution, gender and stress-induced changes in the inflammatory response system. Psychol Med 2002; 32: 919-928.
43. Hermann GE, Rogers RC: TNFalpha: a trigger of autonomic dysfunction. Neuroscientist 2008; 14: 53-67.
44. Murr C, Fuchs D, Gossler W, Hausen A, Reibnegger G, Werner ER, Werner-Felmayer G, Esterbauer H, Wachter H: Enhancement of hydrogen peroxide-induced luminol-dependent chemiluminescence by neopterin depends on the presence of iron chelator complexes. FEBS Lett 1994; 338: 223-226.
45. Weiss G, Fuchs D, Hausen A, Reibnegger G, Werner ER, Werner-Felmayer G, Semenitz E, Dierich MP, Wachter H: Neopterin modulates toxicity mediated by reactive oxygen and chloride species. FEBS Lett 1993; 321: 89-92.
46. Schobersberger W, Hoffmann G, Grote J, Wachter H, Fuchs D: Induction of inducible nitric oxide synthase expression by neopterin in vascular smooth muscle cells. FEBS Lett 1995; 377: 461-464.
47. Schobersberger W, Hoffmann G, Hobisch-Hagen P, Bock G, Volkl H, Baier-Bitterlich G, Wirleitner B, Wachter H, Fuchs D: Neopterin and 7,8-dihydroneopterin induce apoptosis in the rat alveolar epithelial cell line L2. FEBS Lett 1996; 397: 263-268.
48. Baier-Bitterlich G, Fuchs D, Murr C, Reibnegger G, Werner-Felmayer G, Sgonc R, Bock G, Dierich MP, Wachter H: Effect of neopterin and 7,8-dihydroneopterin on tumor necrosis factor alpha induced programmed cell death. FEBS Lett 1995; 364: 234-238.
49. Fava GA, Sonino N: Psychosomatic medicine: a name to keep. Psychother Psychosom 2010; 79: 1-3.
50. Heins MJ, Knoop H, Prins JB, Stulemeijer M, van der Meer JW, Bleijenberg G: Possible detrimental effects of cognitive behaviour therapy for chronic fatigue syndrome. Psychother Psychosom 2010; 79: 249-256.
51. Nater UM, Jones JF, Lin JM, Maloney E, Reeves WC, Heim C: Personality features and personality disorders in chronic fatigue syndrome: a population-based study. Psychother Psychosom 2010; 79: 312-318.
52. Honkalampi K, Lehto SM, Koivumaa-Honkanen H, Hintikka J, Niskanen L, Valkonen-Korhonen M, Viinamaki H: Alexithymia and tissue inflammation. Psychother Psychosom 2011; 80: 359-364.
53. Cella M, Chalder T, White PD: Does the heterogeneity of chronic fatigue syndrome moderate the response to cognitive behaviour therapy? An exploratory study. Psychother Psychosom 2011; 80: 353-358.
54. Lichtenberg P, Belmaker RH: Subtyping major depressive disorder. Psychother Psychosom 2010; 79: 131-135.